Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes / 南方医科大学学报
Journal of Southern Medical University
;
(12): 1050-1051, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-270213
ABSTRACT
<p><b>OBJECTIVE</b>To study the effect of rosiglitazone on serum high-sensitivity C-reactive protein (hs-CRP), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha) and insulin resistance in obese patients with newly diagnosed type 2 diabetes.</p><p><b>METHODS</b>This study involved 118 patients with newly diagnosed type 2 diabetes and obesity, who were randomly assigned into two groups for a 12-week treatment with rosiglitazone (4 mg/day, group A) or sulfonylureas (group B). Serum hs-CRP, IL-1beta, IL-6, TNF-alpha, fasting plasma glucose (FPG) and fasting insulin (FINS) were measured before and after the treatment. Insulin resistance index was calculated according to the HOMA Model.</p><p><b>RESULTS</b>In group A, rosiglitazone treatment resulted in significantly reduced serum hs-CRP, IL-1beta, IL-6, TNF-alpha, FPG and insulin resistance index (P<0.01). No difference in FPG was found between the two groups after the treatment (P>0.05), but serum hs-CRP, IL-1beta, IL-6, TNF-alpha and insulin resistance index were significantly lower in group A than in group B (P<0.05).</p><p><b>CONCLUSION</b>Rosiglitazone can decrease FPG, reduce the inflammation reaction and improve insulin resistance in obese patients with type 2 diabetes.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Blood
/
C-Reactive Protein
/
Insulin Resistance
/
Interleukin-6
/
Tumor Necrosis Factor-alpha
/
Thiazolidinediones
/
Therapeutic Uses
/
Diabetes Mellitus, Type 2
/
Drug Therapy
/
Interleukin-1beta
Type of study:
Diagnostic study
/
Prognostic study
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Journal of Southern Medical University
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS